Return to News
Argos Therapeutics Announces Three Presentations at
BIO 2008 International Convention
Durham, NC- June 10, 2008 — Argos Therapeutics today announced that Jeffrey Abbey, M.B.A., J.D., Vice President of Business Development, will participate in three presentations during the BIO 2008 International Convention, held June 17-20, 2008, at the San Diego Convention Center.
Mr. Abbey will be on the panel in a breakout session titled, “Not Lost in Translation: Forging Japanese Pharma and Western Biotech Collaborations,” in which he will discuss Argos´ ongoing collaboration with Kirin Pharma Company, Ltd. This session will take place on June 17 from 8:15-9:45 am PDT in Room 24BC.
Mr. Abbey will also present Argos´ proprietary manufacturing process for optimizing dendritic cells for maximum clinical efficacy and commercial viability. His presentation will be at the BioProcess Zone Theater, in Booth #2438 in the exhibition hall, on June 17 from 4:45-5:10 pm PDT.
Lastly, Mr. Abbey will provide an update on the Company´s immunotherapy programs in the BIO Business Forum on June 19 at 1:45 pm PDT in Room 2. He will discuss Argos´ personalized immunotherapy technology platform, Arcelis™, as well as its CD83 recombinant protein, an immunosuppressant for autoimmune disease and transplantation.
Additional details on the convention can be found at www.bio2008.org
About Argos Therapeutics, Inc.
Argos is an immunotherapy company developing new treatments for cancer, infectious and
autoimmune diseases, and transplantation rejection. The Company has generated multiple
platform technologies and a diverse pipeline of products based on its expertise in the biology of
dendritic cells — the master switch that turns the immune system on or off.
MacDougall Biomedical Communications
print friendly version
# # #